Progression of molecular genetics in Ph-like acute lymphoblastic leukemia: reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.02.003
- VernacularTitle:Ph样急性淋巴细胞白血病的分子遗传学进展:第56届美国血液学会年会报道
- Author:
Yang ZHANG
;
Hongxing LIU
- Publication Type:Journal Article
- Keywords:
Ph-like acute lymphoblastic leukemia;
Tyrosine kinase inhibitors;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(2):74-78
- CountryChina
- Language:Chinese
-
Abstract:
The event free survival and overall survival rate of acute lymphoblastic leukemia (ALL)have been improved significantly based on the risk stratify diagnosis and treatment.But there are still some patients suffering therapeutic failure and relapse.With the great development of genome sequencing technology,more and more genetic aberrations behind the refractory and relapse ALL have been identified.Ph-like ALL is charactered with gene expression profile similar to that of BCR-ABL1 positive ALL,involving abnormal activation of cytokine receptor and tyrosine kinase.It has been proved that treatment combined with Tyrosine kinase inhibitors (TKIs) can significantly improve the poor prognosis.Ph-like ALL is one of hot topics during the 56th American Society of Hematology (ASH) annual meeting in 2014.Progression in molecular genetics for Ph-like ALL will be introduced together with the author' s research experience.
